Evaluation of the Osteoinductivity of Atorvastatin Combined With β-TCP (NCT06382974) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluation of the Osteoinductivity of Atorvastatin Combined With β-TCP
Egypt10 participantsStarted 2024-12
Plain-language summary
This case series study aims to evaluate the local effects of Atorvastatin (which belongs to the family of lipid-lowering drugs, known as statins) combined with β-TCP (which is a synthetic osteoconductive bone graft), on the volume of the residual bone defects and on hastening the bone regeneration after radicular jaw cyst enucleation using CBCT-based volumetric analysis to calculate the shrinkage rate of these defects.
Who can participate
Age range18 Years – 40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male and female patients
✓. Patients 18 to 40 years old
✓. Radicular cyst with a maximum diameter from 1.5 to 4.0 cm;
✓. Focal teeth were preserved with root canal treatment;
✓. No previous surgical treatment of the cyst site;
✓. No evidence of acute inflammation;
✓. In good physical status and oral health;
✓. Regular attendance at control visits
Exclusion criteria
✕. Patients \< 17 years old
✕. Radicular cyst with a maximum diameter \< 1.5 cm.
✕. Pregnancy or lactation
✕. Aggregate systemic pathologies such as diabetes, thyroid disorders, and bone metabolism diseases, among others;
✕. Patients taking calcium, bisphosphonates, glucocorticoids, or other drugs that can interfere with the metabolism of bone;
✕. Patients with uncontrolled periodontal conditions, endodontic conditions, and other oral disorders;
✕
What they're measuring
1
The Rate of shrinkage of the residual bone defect
Timeframe: 3 moths post-operatively and 6 months post-operatively